VERAXA Biotech Receives Key Regulatory Advice for BiTAC-TCE Cancer Therapy
July 20, 2026 — VERAXA Biotech receives Scientific Advice from Paul-Ehrlich-Institute for its BiTAC-TCE cancer therapy, advancing toward clinical development with promising preclinical data.